1. Scrip
  2. >>Business
  3. >>Earnings

MorphoSys Upbeat Despite Partner Failures In Alzheimer's And Rheumatoid Arthritis

High Hopes For Myelofibrosis Candidate Pelabresib

 
• By Kevin Grogan

Monjuvi is still struggling to make progress commercially and the hopes of lucrative royalty streams from partners Roche and GSK have dried up but MorphoSys is keeping faith in its fully owned pipeline.

MorphoSys
• Source: Shutterstock

MorphoSys AG has had a tough time of late, with high-profile drugs partnered with GSK plc and Roche Holding AG failing in late-stage trials, but the German biotech remains confident in the potential of its proprietary pipeline.

The Munich-based firm's miserable autumn began when GSK decided last month to abandon the rheumatoid arthritis otilimab after reviewing data from two Phase III studies which tested two doses of the granulocyte-macrophage colony-stimulating factor (GM-CSF) antibody against placebo and two JAK inhibitors, Pfizer Inc.’s Xeljanz (tofacitinib) and Sanofi/Regeneron Pharmaceuticals, Inc.’s Kevzara (sarilumab). The drug, which was licensed from MorphoSys in 2013, had been touted by GSK as a future blockbuster

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

Takeda Plans US Investment But Sees Little Impact From Tariffs

 
• By Alaric DeArment

The Japanese drug maker is on track for three pivotal Phase III readouts and two regulatory submissions in 2025.

Q1 S&E In Brief: Tracking New Launches And Catalysts In Biopharma

 
• By Jessica Merrill and Joseph Haas

Neurocrine, Madrigal and Vanda updated investors on new drug launches, while Cytokinetics talked to investors about an FDA extension for aficamten.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.

Sarepta Slammed By Double Blow: Elevidys Sales Miss, Prasad’s CBER Appointment

 
• By Mandy Jackson

Sarepta’s stock price was battered after Vinay Prasad was appointed to lead the US FDA’s CBER, then the company’s shares were bruised when Q1 Elevidys sales came in below consensus.

More from Business